At BioInnovation Institute, we support early-stage life science start-ups that contribute to improving human health for the benefit of people and society. But which trends do we currently see in the therapeutics field? We asked our Senior Associate, Matthias Wulf, who highlighted five companies.
Probmet: PrOBMet is a spin-out from the RCSI University of Medicine and Health Sciences that draws on the collaborative expertise of the Beaumont RCSI Cancer Centre. The company is developing targeted treatments for breast cancer brain metastatic patients.
Ousia Pharma: A toxicology-stage life science company focused on developing innovative medicines for treating metabolic and neurological disorders. Ousia Pharma utilizes a proprietary targeting approach in which peptides deliver modulators of neuroplasticity to drive potent and sustained disease-modifying benefits for patients suffering from obesity and cognitive disorders.
Notify Therapeutics: By targeting the early and hormone-independent phase of egg maturation, Notify Therapeutics aims to develop a first-in-class treatment for infertile women who do not benefit from standard hormone therapy.
Myopax: Myopax possesses proprietary muscle stem cell technology for advanced regenerative therapies to combat the devastating consequences of muscle diseases.
Tetrakit Technologies: develops the next generation of radioactive drugs to find and destroy cancer tumors. Its mission is to enable better, safer, and more cost-effective theranostic radiopharmaceuticals for patients with advanced cancer.